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ABSTRACT 
        The goal of part I of this thesis was to isolate pure anti cancer compounds from the Russian 
plant Sanguisorba officinalis. This plant was selected for investigation because it showed 100% 
activity against leukemia (L1210 mouse leukemia cells) during the preliminary screening of 
approximately 100 Russian plant extracts. This work has resulted in the isolation of novel 
compound 11 using traditional chromatography techniques. Compound 11 was characterized 
with spectroscopic techniques such as IR, 1H NMR, 13C NMR, DEPT, DQCOSY and MS.  
Compound 11 was assigned the structure dipentyl 2-(4-(pentan-3-yl) phenyl) malonate. 
        The goal of part II of this thesis was to synthesize novel ethers of podocarpic acid. Ethers 
are of great interest in biological studies and pharmaceutical applications because of their wide 
variety of uses in the treatment of various diseases. A novel family of ether derivatives was 
synthesized using podocarpic acid (a natural tricyclic diterpene derived from podocarpus 
species) as a template. Novel ether derivatives of podocarpic acid were synthesized from 
podocarpic acid in three steps. The first step involved methylation of podocarpic acid with 
dimethyl sulfate to form methyl-o-methyl podocarpate. The second step was iodination of 
methyl-o-methyl podocarpate with iodine in presence of a mercury catalyst to form 13-iodo 
methyl-o-methyl podocarpate. This was followed by formation of novel aliphatic ethers using a 
copper catalyst. Thus this research had led to the discovery of new methodology for synthesis of 
three novel aliphatic ether derivatives of podocarpic acid. These ethers will be tested for their 
biological activity against various types of cancer, tuberculosis by National Institutes of Health. 
. 
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PART I: ISOLATION OF DIPENTYL 2-(4-(PENTAN-3-YL) PHENYL) 
MALONATE FROM SANGUISORBA OFFICINALIS LABILL 
1. Introduction 
1.1. Natural Products and Drug Discovery: 
 Modern medicine has had great success in discovering the new drugs from natural 
sources (animals, plants and microorganisms) as well as synthetic methods for the 
treatment of various infectious diseases like malaria, HIV, tuberculosis and cancer. 
Throughout the history of mankind there has been a rich tradition in the use of herbal 
medicine for the treatment of human ailments1 with the first records dating from about 
2600 BC in Mesopotamia2. This could possibly be because drugs obtained from plants 
may have fewer side effects and may reduce the possibility of microorganisms 
developing resistance against drugs. Today, plant-based medicines are being used by 
approximately eighty percent of the world’s population for primary healthcare. Over 
50% of the FDA approved anticancer drugs since 1960 have come from natural 
resources, mainly terrestrial plants3. Approximately one-third of the top-selling drugs in 
the world are natural products or their derivatives4. Approximately twenty five percent 
of the prescription drugs in the United States are the active constituents of higher 
plants5. Some plant based medicines are quinine (the anti malarial drug from Cinchona 
bark species) digitoxin (used for treatment of congestive heart failure and isolated from 
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Digitalis purpurea) taxol (the anti- tumor drug from Taxus brevifolia) and 
ephedrine,(the anti asthma drug from Ephedra sinica). 
1.2. Etiology of Cancer and treatment: 
Cancer is the second leading cause of death in the United States. Approximately thirty 
percent of the people develop cancer during their life time6. Cancer results from the 
uncontrollable abnormal growth of cells. Because of no differentiation between cancer 
and normal cells, cancer cells upon metastasis spreads to other tissues and organs. 
Hence cancer is a life threatening pandemic disease and must be treated. There are 
many anti cancer drugs, with a majority7 of them derived from plant and animal 
sources. Anticancer drugs act by interfering with cancer cell growth and reproduction. 
There are many advanced methods for the treatment of cancer; the method to use 
depends on the decision made by a panel of doctors based on the type of cancer and its 
intricacies. 
The most common types of cancer include colorectal cancer, breast cancer, prostate 
cancer, lung cancer, skin cancer and leukemia. Leukemia, the most common type of 
blood cancer affects about 30% of children in the United States. Crowley8, the author of 
the book Introduction to human diseases, has explained the nature of the disorder 
leukemia. The term leukemia refers to a neoplasm of hematopoietic tissue. Leukemia is 
a malignant disease of bone marrow and blood, characterized by uncontrolled 
accumulation of white blood cells. There are two types of white blood cells called 
myeloids, which kill bacteria and lymphocytes, which have a significant role in the 
management of immune system. In contrast to solid tumors, which form nodular 
 2
deposits, leukemic cells diffusely infiltrate the bone marrow and lymphoid tissues, spill 
over into the blood stream, and infiltrate through out the various organs of the body. 
There are more than dozen types leukemia, out of these, four9 types of leukemia occur 
most frequently, including acute lymphocytic leukemia (ALL), chronic lymphocytic 
leukemia (CLL), acute myelogenous leukemia (AML) and chronic myelogenous 
leukemia (CML). Leukemia is the most common cancer that affects children under the 
age of 19. About 78% of childhood leukemias10 are of ALL type.  ALL results when 
DNA of a cell in bone marrow has genetic injury. This involves accumulation of cells 
called lymphoblasts or leukemic blasts, which fail to function as normal red blood cells 
results in anemia, thrombocytopenia, and neutropenia in the blood. Myeloblastic 
leukemia or myelogenous leukemia (AML) develops when there is a defect in the cells 
in the bone marrow. AML occurs more often in adults. CML is known as 
myeloproliferative disorder, the disease in which bone marrow cells proliferate outside 
the bone marrow tissue. CLL results from gradual accumulation of lymphocytes. The 
leukemic cells may be mostly mature and can perform certain functions as in chronic 
lymphocytic or myelogenous leukemia or may be extremely primitive as in acute 
lymphocytic or myelogenous leukemia and can not perform any functions and must be 
treated immediately. The overproduction of white cells in leukemia may be reflected in 
the blood by a very high white blood cell count. In some cases of leukemia white cells 
multiplication mostly confined to bone marrow as in acute or chronic myelogenous 
leukemia. 
      Though treating leukemia is difficult, there is a hope to get success. Management of 
disease currently relies on a combination of early diagnosis either by bone marrow 
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biopsy or lumbar puncture and aggressive treatment, which may include one or more 
treatments such as surgery, radiation therapy, chemotherapy, immunotherapy and bone 
marrow transplantation available to treat leukemia. Researchers are focusing their 
studies on developing new effective methods or drugs to treat leukemia. Surgery 
involves removal of the whole tumor to avoid spreading of cancer to other parts of the 
body. Radiation therapy is done by passing high energy particles or waves, such as γ 
rays, x rays, electrons or protons to destroy or damage cancer cells. This works by 
breaking the strand of DNA inside the cancer cell, which prevents the growth and 
division of cancer cells. Immunotherapy (biological therapy) has proven useful in 
treating cancer within last few decades. This is the treatment done by using certain parts 
of immune system of the patient’s body by stimulating the immune system or by using 
the man made immune system proteins. Nowadays three types of immune therapy are 
available immune cell administration, use of vaccines and antibody treatment. 
Immunotherapy11 is the most promising treatment for leukemia and certain other 
cancers like kidney cancer, breast cancer, prostate cancer, colorectal cancer and lung 
cancer. Bone marrow transplantation is required for certain leukemia patients if their 
bone marrow has destroyed by disease, chemotherapy or radiation therapy. This is the 
best method available for some patients with acute leukemia and chronic granulocytic 
leukemia who have not responded to other conventional treatments12. The patient’s own 
bone marrow is destroyed by large doses of anti cancer drugs and radiation. Then 
several hundred milliliters of bone marrow are aspirated from multiple sites in the 
pelvic bones of suitable donor, filtered to break up the clusters of marrow cells and 
form a homogeneous suspension of individual cells, and then inject to the patient. The 
 4
marrow cells circulate in the patient’s blood but they become stable and grow in the 
marrow, produce new population of leukemia free marrow cells. As the bone marrow of 
donor is a foreign tissue, to avoid rejection, patient’s immune system should be 
suppressed during transplantation. The last and most viable method for treating 
leukemia is Chemotherapy. Chemotherapy means taking medicines or drugs orally or 
intravenously to treat cancer. Cancer chemotherapy has been there to treat cancer since 
195013. Chemotherapy is helping cancer patients to have a prolonged happy life. Every 
method in use for the treatment of cancer involves chemotherapy at some stage during 
the treatment period. 
A natural product that has been discovered recently by Shinya Kimura13 et al for        
treatment of leukemia is GUT 70 (1), isolated from the stem bark of Callophylum       
brasiliense, which was collected from Brazil. GUT 70 (1) is a tricyclic coumarin       
named 5-methoxy, 2, 2-dimethyl-6- (2-methyl-1-oxo-2-butenyl) -10-propyl-2H, 8H-       
benzo (1,2-b; 3, 4-b) dipyran-8-one, which has shown antileukemic activity against    
five human leukemic cell lines (BV 173, K562, KALM 6, Hl-60 and SEM).                                                  
       
o
o
o
o
 
(1)  GUT-70 
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Amooranin (2) is a novel plant triterpenoid that was isolated from Amoora rohituka by 
Chappail Ramachandran14 et al. Compound 2 exhibited potent anti leukemic        
activity as was demonstrated by inducing G2 + M phase arrest during cell cycle in        
leukemia and colorectal carcinoma. 
 
 
(2) Amooranin 
 
Zhang J T 15 reported that Indirubin (3) was isolated from the leaves of Indigo naturalis 
which is a native Chinese plant. Compound 3 exhibited anti leukemic activity without 
bone marrow inhibition. 
 
N
H
O
NH
O  
(3) Indirubin 
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Aryanti16, Bintag and Maria reported that Artemisinin (4), (a sesquiterpene lactone), 
obtained from the transformed root of cultured  Artemisia cina that was  produced by 
infection of stems and leaves with agro bacterium rhizogenes. Compound 4 had a high 
inhibition activity on leukemic K562 cells with the IC50=1ppm 
 
O
O
O
O OH
H
H
 
(4) Artemisinin 
 
 Two indole quinoline derivatives cryptolepine (5) and neocryptolepine (6) were      
isolated from the roots of theAfrican plant Cryptolepis sanguinolenta. Their     
cytotoxicity was tested on murine and human leukemia cells. Christian bailey et al17        
reported that cryptolepine (5), and to the lesser extent neocryptolepine (6), showed      
antileukemic activity by massive accumulation of p388 cells in G2+M phase of cell      
cycle. 
N
H
N+
H3C
 
(5) Cryptolepine 
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 N
H
N+
CH3
 
(6) Neocryptolepine 
 
Goniothalamin (7)18,19was isolated from Bryonopsis laciniosa by Ali Abdul et al.  The 
cytotoxicity of compound 7 was investigated on a T-lymphoblastic leukemia cell line. 
The results were compared to Etoposide anticancer activity, which indicated that 
Goniothalamin (7) had a potent apoptic activity. This was confirmed by observing the 
inter nucleosomal DNA fragmentation.  
 
O O
H
  
(7) Goniothalamin 
 
The novel norilludalane sesquiterpene puraquinonic acid (8) was isolated by Becker 
and coworkers20 from mycelial cultures of Basediomycete mycenae Pura. Puraquinonic 
acid (8) induces differentiation of 30-40% of HL-60 cells into granulocyte or 
monocyte/macrophage like cells at 380µm. U-937 cells were affected to a lesser extent 
at the same concentration. 
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OO
COOH
HO
 
(8) Puraquinonic acid 
 
Erkel and coworkers21 isolated nidulal (9) novel inducer of differentiation of human 
HL-60 promyelocytic leukemia cells) from the fermentation of basidiomycete Nidula 
candida, together with small quantities of niduloic acid (10). Both are bisabolane 
sesquiterpenes.They reported that nidulal(9) activated transcription factor complex AP-
1 mediated expression of secreted alkaline phosphatase in COS-7 cells.  
 
CHO
O
H3C O
O
O
 
(9) Nidulal 
 
 
       
COOH
O
H3C
HOOC
 
Thus a variety of novel natural products have been isolated that may yield new drugs for 
the treatment of leukemia. 
(10) Niduloic acid 
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1.3. The Goal of This Research: 
The goal of this work was to isolate pure compounds, which can inhibit the growth of 
cancer cells, from methylene chloride extract of Sanguisorba officinalis labill. This 
plant was selected for investigations as the preliminary screening of methylene chloride 
extract of this plant from Russia had shown hundred percent activity against leukemia 
and sixty seven percent anti thrombin activity22. 
1.4. Sanguisorba Officinalis and its origin: 
Although this plant material has collected from Russia, Sanguisorba is native to China 
belongs to family Rosaceae, a large family of 95 genera and 2800 species23 
Sanguisorba officinalis labill contains about 25 species. They grow in moist meadows 
and shady places, almost all over Europe. It grows in a wild from Maine to Minnesota 
in USA. The aborigines (native Chinese) have traditionally used sanguisorba to heal 
wounds and to treat fungal infections. Mainly they used in cure of heavy periods and 
hemorrhage. The extracts of Sanguisorba have been used as food additives, to make tea 
and in cosmetic formulations.  Recently this plant has got much attention to investigate 
its medicinal uses. Research data has demonstrated that the extracts exhibit various 
biological activities such as antidiarrheal, antibacterial and antiemetic. It is a valuable 
astringent and is used for gastrointestinal problems, diarrhea, dysentery, ulcerative 
colitis and abdominal uterine bleeding. The crude extracts from Sanguisorba officinalis 
showed significant antimicrobial activity24 against both Gram-positive and Gram-
negative bacteria, when tested against five species of microorganisms (Staphylococcus 
aureus, Pseudomonas aeruginosa, Escheria coli, Bacillus subtilis, Candida albicans ).  
 10
1.5. Previously isolated compounds from Sanguisorba Officinalis: 
Previously several compounds have been isolated from Sanguisorba Officinalis, 
including ursolic acid25, sanguisorbigenin, 2,4-dihydroxy-6-methoxy acetophenone, 
3,3’,4-tri (O-methyl) ellagic acid, oleanolic acid, masilinic acid26, sanguisorbin, 
terpenyl acetate27 and grandinin. The structures of these compounds shown in table 1. 
Ursolic acid is a triterpenoid that present in especially waxy coatings of leaves and in 
fruits, such as apples and pears. It can serve as insect repellant and anti microbial 
agent28. Although triterpenoids have limited medicinal use, recent studies indicate them 
as potential drug leads29. Ursolic acid has shown significant cytotoxicity in the 
lymphocytic leukemia cells P388 with ED50 3.15mg/mL, L1210 with ED50 4.00 
mg/mL30. The anti tubercular activity of ursolic acid has also been reported31. 
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     Table 1 Structures of previously isolated compounds from Sanguisorba officinalis 
 
General structure Compound name 
 
 
 
 
Ursolic acid 
 
 
 
              
Maslinic acid 
 
 
 
 
11,12-Dehydro ursolic acid 
lactone 
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Me
C
MeAcO
Me
 
 
Terpinyl acetate 
MeMe
Me
 
 
α-pinene 
COOH
HO
HO
OH  
 
Gallic acid 
O
OH
OH
OH
OH
HO
 
 
 
Catechin 
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2. Results and Discussion 
Sanguisorba officinalis was selected for this investigation because preliminary 
screening of the methylene chloride extract from this plant had shown hundred percent 
activity against leukemia when it was tested on mouse leukemia cells. Dried leaves of 
the plant material were collected from Russia and extracted with methylene chloride 
followed by methanol in a soxhlet apparatus for 12 hours. The solvent was removed in 
vacuum to obtain methylene chloride and methanol extracts. The methylene chloride 
extract was chromatographed on silica gel and then eluted with mixed solvents such as 
hexane, methylene chloride; chloroform and methanol in the order of increasing 
polarity.107 fractions were obtained. The eluent fractions were collected and monitored 
by TLC on silica gel with different solvent systems ranging from 25%:75% hexane: 
methylene chloride to 50%:50% hexane: methylene chloride and the results were 
observed under UV light. Based on these results fractions 1-27 were mixed and further 
chromatographed in a small liquid chromatography column to obtain twenty fractions. 
From the resultant fractions, a pure compound was isolated. This compound was a 
highly viscous liquid with pale yellow color and was proved to be dipentyl 2-(4-
(pentan-3-yl) phenyl) malonate based on the spectroscopic data obtained. Normal phase 
open column chromatography results are shown in table 2 and table 3. 
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       Table 2 Column Chromatography (I) of Sanguisorba Officinalis Labill 
Fractions Eluent Weight (grams) 
F 1-7 100% hexane 0.32 
F 8-11 20% CH2Cl2 in hexane 1.69 
F 12-20  30% CH2Cl2 in hexane 3.06 
F 21-25 40% CH2Cl2 in hexane 1.34 
F 26-30 50% CH2Cl2 in hexane 0.56 
F 31-40 60% CH2Cl2 in hexane 2.78 
F 41-50 70% CH2Cl2 in hexane 0.68 
F 51-59 80% CH2Cl2 in hexane 3.57 
F 60-74 90% CH2Cl2 in hexane 3.20 
F 75-79 100% CH2Cl2  1.84 
F 80-84 50% CH2Cl2 in CHCl3 2.34 
F 85-89 75% CH2Cl2 in CHCl3 2.17 
F 90-93 100% CHCl3 1.98 
F 94-99 50% CHCl3 in CH3OH 2.20 
F 100-107 100% CH3OH 3.12 
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        Table 3 Column Chromatography (II) of Sanguisorba Officinalis Labill 
Fractions Eluent Weight (grams) 
F 1-2 100% hexane 0.34 
F 3-4 20% CH2Cl2 in hexane 0.38 
F 5-6 50% CH2Cl2 in hexane  0.28 
F 7-9 75% CH2Cl2 in hexane 0.52 
F 10 100% CH2Cl2  0.48 
F 11-13 50% CH2Cl2 in CHCl3 1.25 
F 14-15 75% CH2Cl2 in CHCl3  1.54 
F 16 100% CHCl3 0.87 
F 17-18 50% CHCl3 in CH3OH 0.68 
F 19 75% CHCl3 in CH3OH 0.43 
F20 100% CH3OH 0.62 
 16
  
               Figure 1 GC of dipentyl 2-(4-(pentan-3-yl) phenyl) malonate(11). 
 
The purity of the isolated compound was evaluated with gas chromatography. The GC 
 
 showed a single peak with retention time tr = 5.68 min. 
 17
 
 
           Figure 2 HPLC of dipentyl 2-(4-(pentan-3-yl) phenyl) malonate(11). 
 
High performance liquid chromatography (HPLC) was used for separating and 
determining species in different materials. Normal phase HPLC was performed by 
using different compositions of several solvent systems that are normally used and the 
best results were obtained with hexane and methylene chloride (20 % to 80%).The 
chromatogram is shown in figure 4. 
 
 18
            Figure 3 UV spectrum of dipentyl 2-(4-(pentan-3-yl) phenyl) malonate(11). 
 
The UV spectrum of dipentyl 2-(4-(pentan-3-yl) phenyl) malonate (11) showed the 
absorption maxima at λmax: 200 nm, 268 nm, 298 nm, which suggested the presence of 
a conjugated system.  
 19
             Figure 4 IR spectrum of dipentyl 2-(4-(pentan-3-yl) phenyl) malonate(11). 
 
The IR spectrum has showed absorption maxima at λmax  1740 cm-1 for an ester carbonyl 
group, 1121 cm-1 and 1267 cm-1 for C-O stretch and 1465 cm-1 and 1600 cm-1 for an 
aromatic system. 
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              Figure 5 1H NMR spectrum of dipentyl 2-(4-(pentan-3-yl) phenyl) malonate(11). 
 
1H NMR, 13C NMR, DEPT and DQCOSY data were obtained to complete the structure 
proof of compound 11. The spectra were run in deuterated chloroform and deuterated 
acetone. The 1H NMR showed signals between 0.8 and 1.1 ppm for four methyl groups,    
between 1.2 and 1.6  ppm for eight methylene groups, between 2.2 and 2.8ppm for two 
methine groups and between 4.1 and 4.3 ppm for two methylene groups attached to 
oxygen.  The signals at δ 7.5 and δ 7.7 correspond to aromatic protons. 1H NMR is 
shown in Figure 5. 
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          Figure 6 13C NMR spectrum of dipentyl 2-(4-(pentan-3-yl) phenyl) malonate(11). 
 
The DEPT 13C NMR spectrum (Figure 7) revealed four methyl carbons at δ 11.436 and 
δ 14.52. The methylene carbons appeared at δ 23.428, δ 24, δ 29.348 and δ 30.775, 
while the methine carbons appeared at δ 44.9, δ 128.9 and δ 130.9. The quaternary 
carbons appeared at δ 132.5 and the ester group carbon appeared at δ 167.7. The 13C 
NMR spectrum is shown in Figure 6. 
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          Figure 7 13C DEPT spectrum of dipentyl 2-(4-(pentan-3-yl) phenyl) malonate (11). 
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        Figure 8  DQCOSY spectrum of dipentyl 2-(4-(pentan-3-yl) phenyl) malonate (11). 
 
The DQCOSY showed that the methylene carbons attached to oxygen are attached to 
methylene groups and benzene is disubstituted. Some of methylene groups attached to 
methyl groups. 
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          Figure 9  Mass spectrum of dipentyl 2-(4-(pentan-3-yl) phenyl) malonate (11). 
 
The basic fragmentation pattern of proposed structure of dipentyl 2-(4-(pentan-3-yl) 
phenyl) malonate is illustrated in figure 10. 
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Figure 10  Scheme summarizing the mass fragmentation pattern of dipentyl 2-(4-pentan-
3-yl) - phenyl) malonate (11). 
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The UV, IR, 1H NMR, 13C NMR and MS data confirms the structure of compound 11 as 
dipentyl 2-(4-pentan-3-yl) phenyl) malonate. 
 
O
O
O
O
 
(11) Dipentyl 2-(4-pentan-3-yl) phenyl) malonate. 
  
Figure 11  The proposed structure for compound 11, isolated from Sanguisorba 
officinalis 
        Structure elucidation of compound 11 was done as follows. The UV spectrum 
showed the absorption maxima at λmax: 200 nm, 268 nm, 298 nm, which suggested the 
presence of a conjugated system. The IR spectrum has showed absorption maxima at 
λmax  1740 cm-1 for an ester carbonyl group, 1121 cm-1 and 1267 cm-1 for C-O stretch 
and 1465 cm-1 and 1600 cm-1 for an aromatic system. Hence at this juncture, the 
presence of benzene ring and ester groups were confirmed. 
         and          -C-O-R
O 
To know which R group was attached to ester group and benzene ring, the 1H NMR 
was performed. This showed the presence of Para disubstituted benzene ring by 
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showing doublet of doublets in between δ 6.0 ppm and δ 8.0ppm also showed the 
presence of 4 methyl groups, 8 methylene carbons, 2 methine carbons and 2 CH2-O 
moieties. At this point part of the compound 11 structure was as shown below. 
 
        
  
R
R'
R and R’ groups are different. For further information about R and R’ groups 13C NMR 
and DEPT were performed. 13C NMR showed 12 different signals indicated that 
compound 11 should be symmetric. The DEPT spectrum showed the presence of 2 
types CH3, 4 types CH2, 1 type CH2–O and 4types CH groups. 
R
R
R'
R'
                  
 
 
 
 
The DQCOSY showed that CH2-O moieties are attached to CH2 carbons. The HRMS 
gave the molecular formula for compound 11 as C24H38O4 and the fragmentation 
pattern was consistent with the mass spectrum obtained. 
Hence from all the above information, by considering carbon-carbon connectivity’s in 
DQCOSY spectrum and mass spectral fragmentation pattern the structure of compound 
11 was confirmed as  dipentyl 2-(4-pentan-3-yl) phenyl) malonate. 
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 3. Experimental 
3.1 General experimental procedure 
UV spectrum was obtained in hexane with a Carry 500 scan UV-NIR 
spectrophotometer and the absorption maximum was given in nm. IR spectrum was 
recorded on a Perkin Elmer Spectrum One FT-IR spectrometer. The NMR spectra were 
obtained on a Varian 300 MHz and the solvents used were deuterated chloroform and 
deuterated acetone. GC-MS spectra were recorded on Trace GC/Trace DQC from 
Finnegan. A capillary column of RTX-5MS with a length of 15 m and 0.25 mm ID was 
used. The oven temperature was initially set up to 90C for 7 minutes then programmed 
to reach 250C. HPLC was run on Gilson equipment, using a silica gel column normal 
phase and the solvent used was a mixture of hexane and methylene chloride. 
3.2 Extraction, isolation and structure determination  
The plant material, Sanguisorba officinalis, was collected from Russia. The dried 
leaves (1.00 Kg) were extracted with methylene chloride followed by methanol for 12 
hrs by using soxhlet apparatus. After extraction, the solvents were evaporated by using 
rotary evaporator and the residue from both extracts was collected. 97 g and 124 g of 
residues were obtained from methylene chloride and methanol extracts respectively. 
Then open column chromatography was carried out on silica gel (E.Merk, 70-230 
mesh). 107 fractions were collected by using different solvent systems in the order of 
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increasing polarity. All fractions were analyzed by TLC. Fractions with same Rf value 
were mixed and again open column chromatography was carried out to isolate a pure 
compound.  Pre-coated preparative silica gel GF-254 plates (20x20 cm, 0.5 mm thick, 
E.Merk) were used for thin layer chromatography.  
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PART II: SYNTHESIS OF A NOVEL FAMILY OF ETHERS OF 
PODOCARPICACID 
1. Introduction 
1.1 The Goal of this research: 
The goal of this research was to synthesize a novel family of ethers of podocarpic acid 
by using podocarpic acid as a template. Previous research studies showed that 
podocarpic acid derivatives were biologically active as well as many compounds with 
ether functionality. Therefore the premise of this work was to synthesize a library of 
ethers of podocarpic acid so that their biological activity will be evaluated by the 
National Cancer Institute against 60 human cancer cell lines for their anti tumor activity 
and  by National Institute of Allergy and Infections Diseases for their activity against 
tuberculosis. 
1.2 Natural products and their anti tumor activity: 
Natural products from plants, fungi and bacteria have been used as traditional medicine 
for the treatment of various diseases and cancers. According to annual report on 
medicinal chemistry from the year 1983 to 1994, 60% to 75% of the prescription drugs 
are natural products or their derivatives32. There is a huge supply of unexploited natural 
products with significant biological activity. Many of these compounds have antitumor 
activity33. As an example etoposide (12), antineoplastic agent, a semi synthetic 
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derivative of podophyllotoxin, extracted from root of Podophyllum peltatum, which 
was shown in figure 12.  
 
(12) Etoposide 
 
 
    
         Figure 12 Podophyllum peltatum 
 32
Boik John, the author of the book Natural compounds in cancer therapy34, described  
about seven strategies to cure cancer. Those are: reducing genetic stability, inhibition of 
abnormal gene expression, inhibition of abnormal signal transduction, by encouraging 
normal cell to cell communication, tumor angiogenesis inhibition, inhibition of 
metastasis and increasing the immune response. Some anticancer drugs act by 
inhibiting cancer cells growth and thereby causing cell death or by arresting cancer cell 
proliferation because of molecular target interactions. In contrast, other drugs act by 
inhibiting cell multiplication indirectly by inducing some changes in the local 
environment, make it unfavorable for angiogenesis, invasion or metastasis. 
Breast cancer is a significant health problem for women in the United States and 
through out the world. Although advances have made in the treatment of the disease, 
still breast cancer is the second leading cause of death for women in the United States. 
No vaccine or any other successful method not available for breast cancer treatment. 
Hormone therapy is very important treatment method for breast cancer since it is 
commonly stimulated by estrogens and sex hormones. So, this cancer is treated with 
anti cancer drugs that inactivate estrogens or limit the amount of estrogens in the body. 
The drug blocks steroid hormone action and stops cancer cell replication by altering 
hormone supplies. Tamoxifen is an estrogen antagonist, structurally related to the 
synthetic estrogen diethylstilbestrol. Tamoxifen acts by inhibiting estrogen action that 
is required to reduce the level of bioavailable estradiol that is necessary for breast 
cancer cell growth.   
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1.3 Some pharmaceutically important ethers: 
Polybrominated di phenyl ether reported by Dian Handayani et al54, which is 
antibacterial being active against Bacillus subtilis and anti fungal, being active against 
fungi Cladosporium cucumerinum. Retinyl-2-propynyl ether activity of suppressing 
mammary cancer reported by Fulmer shealy et al55. Morphine is a known analgesic. 
           Table 4 Structures of some bioactive ethers: 
    Structure of the compound    Name of the compound 
HO
O
Br
Br
Br
Br
 
 
O
 
 
 
Retinyl-2-propynyl ether 
HO
O
HO H
N
 
 
 
Morphine 
3, 4, 5-Tribromo-2-(2′-
bromophenoxy) phenol 
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1.4 Podocarpic acid (13) 
Podocarpic acid (13) is a natural conifer resin acid, which was isolated by Oudemans in 
1873 from Podocarpus Cupressinum. It was extracted from ‘kahikatea’ tree 
Podocarpus Dacrydioides and from ‘rimu’ tree Dacrydium Cupressinum. 
 
       Figure 13  Structure of Podocarpic acid (13)                                         
 
         Figure 14 Podocarpus Cupressinum 
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          Figure 15 Podocarpus Dacrydioides 
 
         Figure 16 Dacrydium Cupressinum 
These are fast growing trees endemic in Newzealand, which is geographically shown in 
figure 16 
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 Figure 17 Distribution of Podocarpus (blue areas) in world map  
Podocarpic acid (13) has extracted by methanol from heart wood of podocarpus 
species. Podocarpic acid has been used in Pharmaceutical industry35 and in the 
preparation of soaps, paints and adhesives36. Podocarpic acid (13) is a white solid 
material with melting point 195C. It is a natural diterpenoid with tricyclic framework 
structure of phenanthrene. It has carboxylic acid and phenol functional groups. Because 
of steric hindrance and due to diaxial interaction with C-10 methyl group carboxylic 
acid moiety is unreactive37, 38 as shown below. 
 
 
Figure 18 Podocarpic acid (13) conformation 
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1.5 Previous studies done on podocarpic acid and its derivatives bioactivity: 
Podocarpic acid (13) and its derivative podocarpinol’s (14) oestrogenic activity was 
found back in 1948 by Brandt and Ross39. 
 
(14) Podocarpinol 
Podocarpic acid (13) has been utilized in the synthesis of anti-inflammatory and 
antiviral agents40, 41, 42. Families of novel compounds containing lactones (cyclic esters) 
and lactams (cyclic amides) have been synthesized from podocarpic acid. Examples of 
derivatives of podocarpic acid are nimbiol (15) and winterin (16).  
 
(15) Nimbiol 
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 (16) Winterin 
Hayashi et al43 synthesized the biologically active dilactone, hydroxynagilactone (17) 
from podocarpic acid in 1982.  
 
(17) Hydroxynagilactone 
 
 
Parish and Miles44 reported the antitumor activity of podocarpic acid derivatives such 
as methyl-6α-bromo-7-oxo-O-methyl podocarpate (18) in 1984. They investigated 
compound 18 activity against human epidermoid carcinoma of nasopharynx invitro. 
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 (18) methyl-6α-bromo-7-oxo-O-methyl 
podocarpate 
In 1987, Parish45 et al synthesized several podocarpic acid derivatives, which showed 
fungistatic activity. The most potent activity was shown by 11, 13-dinitropodocarpic 
acid (19). 
 
(19) 11, 13-dinitropodocarpic acid 
In 1997, Eli lily and company conducted a study on the bioactivity of podocarpic acid 
derivatives for treatment of bacterial and viral infections. The most potent46 drugs 
reported were isopropyl-O-methyl podocarpate (20) and methyl-O-6-en-7-oxo-methyl 
podocarpate (21). 
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 (20) Isopropyl-O-methyl podocarpate 
 
 
(21) Methyl-O-6-en-7-oxo-methyl 
podocarpate 
 
In 1998, methyl-O-methyl podocarpate (22) was reported as antiviral agent. This 
compound 22 showed antiviral activity47 by inhibiting replication of cells during 
protein synthesis of influenza A/ Kawasaki virus. 
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 (22) methyl-O-methyl podocarpate 
Adams48 et al., in 2003, synthesized the podocarpic acid derivative 23 to use as an 
antihyperlipidemic agent (to treat conditions like depressed levels of HDL). 
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2. Results and Discussion 
The goal of this research was to synthesize a family of novel ether derivatives of 
podocarpic acid (13) at the C-13 position of the aromatic ring as shown in figure 19. 
 
        Figure 19 Synthesis of ether derivatives of podocarpic acid (13) 
Ethers are of great interest in organic synthesis because of their wide variety of uses. It 
is known that aromatic amides can be prepared from aryl halides49. About hundred 
years ago in 1903 Ulmann50 discovered the coupling of aryl bromide to form biaryl 
compound. In 1926, Goldberg studied the formation of ethers from aryl bromide by 
using copper catalyst. The reaction temperature of about 200C gave low yields of the 
products and separations were difficult. 
Palladium has been known as a catalyst for formation of ethers at moderate 
temperatures with good yield. However palladium catalyst and phosphine ligands are 
expensive. As a result, the search for inexpensive copper catalyst51, 52 was conducted 
for coupling of an aryl halide with an alcohol to make an ether.  
 43
The advantages of copper catalyst are that it is cheap and can be used in versatile 
conditions such as in the presence of moisture or oxygen. Hence a copper catalyst was 
used in the synthesis of novel ether derivatives of podocarpic acid. 
The first step in this process was methylation of podocarpic acid (13) as described by 
Miles53 to form methyl-O-methyl podocarpate (22) as shown in figure 20. 
 
 
                 (13)      (22) 
           Figure 20 Formation of methyl-O-methyl podocarpate (22) 
 
Compound 22 was formed in 84% yield and melting point was 127C. Spectroscopic 
data such as IR, NMR and MS was consistent with the data shown53. 
 Iodination of compound 22 was performed by reacting compound 22 with iodine to 
form 13-iodomethyl-O-methyl podocarpate (23) in 94% yield with a melting point of 
149C. The spectroscopic data was consistent with the data shown. 
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                       (22)       (23) 
         Figure 21 Formation of 13-iodomethyl-O-methyl podocarpate (23) 
Compound 23 was then reacted with a series of aliphatic alcohols (see Table 5) to form 
novel ethers at C-13 of podocarpic acid. 
 
          Table 5  Alcohols used in the synthesis of novel ethers from compound 23
Alcohol Formula 
Methanol CH3-OH 
Ethanol CH3-CH2-OH 
Propanol CH3-CH2-CH2-OH 
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   (23)      (P) 
     Figure 22: General reaction for formation of novel ethers of podocarpic acid   
Table 6 Attempts in the synthesis of ethers with various R groups 
R -CH3 -C2H5 -C3H7
Ether (P) 24 25 26 
     The general reaction involved mixing 1 molar equivalent of compound 23 with 1.5 
molar equivalents of the corresponding alcohol and sodium alkoxide, 0.1 molar 
equivalent of copper catalyst and 2 molar equivalent of potassium carbonate in N, N- di 
methyl formamide at 110C and refluxing for four hours while monitoring the progress 
of reaction with TLC. When the reaction was completed, the reaction mixture was 
allowed to cool and the precipitate was obtained by vacuum filtration. Normal phase 
open column chromatography was carried out on silica gel 70-230 mesh to obtain the 
pure compound. The structure of each product was elucidated by IR, 1H NMR, 13C 
NMR and MS spectroscopy techniques. 
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The reaction with methanol formed a new compound 13-methoxy methyl-O-methyl 
podocarpate (24) in 84% yield with a melting point 143C. The IR, 1H NMR, 13C NMR 
and MS spectra of compound 24 are shown below. 
 
                               (23)        (24) 
 
 
              Figure 23 IR spectrum of compound 24
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 The IR spectrum of compound 24 gave a signal at 1730 cm-1 corresponding to carbonyl 
group of ester. The signals at 1450 cm-1, 1490cm-1 and 1600cm-1 correspond to the 
aromatic ring. Strong absorption at 1200cm-1 corresponds to the C-O bond of ether and 
ester. 
 
(23) 
 
 
          Figure 24 1H NMR spectrum of compound 24
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The 1H NMR spectrum of compound 24 showed an additional peak at δ 3.62 ppm(s) 
corresponding to methoxy group at C-13 position of podocarpic acid, in comparison to 
1H NMR spectrum of compound 23. 
 
              (23) 
 
       Figure 25  13C NMR spectrum of compound 24
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The 13C NMR spectrum of compound 24 gave peak at δ 57.2 ppm corresponding to   
two equivalent carbons of methoxy groups at C-13 and at C-12 of compound 24. The 
chemical shift of aromatic carbons was more downfield compared to compound 23. 
 
m/z 
                                Figure 26  Mass spectrum of compound 24
 
The mass spectrum showed molecular ion m/z at 332.4 corresponding to molecular 
formula of C20H28O4. The peak at m/z 302.1 represented methyl-O-methyl podocarpate 
formed because of cleavage of C-O bond at C-13 position of compound 24. The base 
peak was given at 154.1 corresponding to [M-178]+. Basic fragmentation pattern for 
compound 24 is shown in figure 27. 
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M-31
-OCH3
m/z 332 m/z 301
-2CH3, -COOCH3, 
-OCH3, -C2H2-147
m/z 154
      
                     Figure 27  Fragmentation pattern of compound 24
Therefore from all the spectroscopic data obtained, compound 24 was found to be 13-
methoxy methyl-O-methyl podocarpate. The structure of compound 24 is shown in 
figure 28. 
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 Figure 28   Structure of compound 24
Compound 25 was formed in 88% yield with a m.p of 146C. The IR, 1H NMR, 13C 
NMR, MS spectra of compound 25 are shown in figures 29, 30, 31 and 32 respectively. 
    
          Figure 29 IR spectrum of compound 25
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The IR spectrum of compound 25 gave a signal at 1730 cm-1 corresponding to carbonyl 
group of ester. The signals at 1450 cm-1, 1490cm-1 and 1600cm-1 correspond to the 
aromatic ring. The strong absorption at 1200cm-1 corresponds to C-O bond of ether and 
ester. 
 
(23) 
 
         Figure 30 1H NMR spectrum of compound 25
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The 1H NMR spectrum gave new signal at δ 3.98 ppm (q) which could be assigned to 
the CH2-O moiety that is present in the compound 25. Methyl group attached to CH2-O 
moiety gave signal at δ 1.33 ppm (t). Two methoxy groups from ether and ester gave 
signals at δ 3.85 (s) and δ 3.95 ppm (s) respectively. 
 
(23) 
 
                     Figure 31  13C NMR spectrum of compound 25
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 The 13C NMR of compound 25 showed new signals at δ 65 ppm and 14.8 ppm 
corresponding to CH2-O and CH3 respectively. Signals appeared down field compared 
to compound 23. 
   
m/z 
                         Figure 32  MS of compound 25
 
The mass spectrum of compound 25 showed a molecular ion at m/z 346.4, which was 
consistent with molecular formula C21H30O4. The peak at m/z 302.4 corresponded to 
methyl-O-methyl podocarpate and could be the result of cleavage of the C-O bond at C-
13 of compound 25. The basic fragmentation pattern for compound 25 is shown in 
figure 33. 
 
 55
 M-45
m/z 346
m/z 301
-2CH3, -COOCH3, 
-OCH3, -C2H2-147
m/z 154
Me
COOMe
OCH3
OCH2CH3
 
 
          Figure 33  Basic fragmentation pattern for compound 25
Therefore compound 25 can be confirmed as 13-ethoxy methyl-O-methyl     
podocarpate. The structure of compound 25 is shown in figure 34. 
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 m/z 346
Me
COOMe
OCH3
OCH2CH3
 
                          Figure 34  Structure of compound 25
 
Compound 26 was formed in 84% yield with a m.p of 148C. The IR, 1H NMR, 13C 
NMR and MS spectra  were obtained and shown in figures 35, 36, 37 and 38 
respectively. 
     
                  Figure 35  IR spectrum of compound 26
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The IR spectrum of compound 26 gave a signal at 1220 cm-1, corresponding to the C-O 
group of ether and ester that were present in compound 26. Absorptions for the 
aromatic ring were present at 1400 cm-1, 1490cm-1 and 1600 cm-1. 
 
(23) 
 
                               Figure 36  1H NMR spectrum of compound 26
 The 1H NMR spectrum of compound 26 showed two singlets at δ 6.62 ppm and δ 6.78 
ppm for aromatic protons on benzene ring. The protons of methoxy groups appeared at 
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δ 3.65 and δ 3.78 ppm. The protons of propyl group appeared at, δ 3.95 ppm (t) for the 
methylene group attached to oxygen, δ 1.75 ppm (sextet) for methylene group and δ 
1.10  ppm (t) for methyl group.  
 
(23) 
                          Figure 37 13C NMR spectrum of compound 26
 13C NMR of compound 26 showed twenty two signals for twenty two different carbons 
present in the compound 26. Seven carbons with the chemical shift down field from δ 
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100 ppm. The methylene attached to oxygen gave a signal at δ 73.5 ppm while a methyl 
group came at δ 14.2 ppm. Methylene group absorption was present at δ 22.7 ppm. A 
total fifteen carbons were present with the chemical shift up field from δ 100 ppm. 
m/z 
                       Figure 38 MS of compound 26
 The MS of compound 26 displayed a molecular ion peak at m/z 360.2, which is 
consistent with the molecular formula C22H32O4. The m/z 302.1 resulted from the 
cleavage of C-O bond at C-13 of compound 26. Further fragmentation gave the base 
peak at m/z 154.1 as shown in figure 40. 
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                Figure 39  Basic fragmentation pattern of compound 26
     Therefore the compound 26 can be confirmed as 13-propoxy methyl-O-methyl  
     podocarpate. Structure of compound 26 is shown in figure 40. 
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                               Figure 40 Structure of compound 26
In the summary the reaction of 13-iodo methyl-O-methyl podocarpate (23) with 
aliphatic alcohols gave ether derivatives of podocarpic acid in high yield (between 84 
and 88 %). Three new ether derivatives of podocarpic acid were synthesized and their 
activity against cancer will be tested by National Cancer Institute against 60 cancer cell 
lines and activity against tuberculosis will be performed  by National Institute for 
Allergies, Infections and Diseases. Thus this work may result in a new drug lead useful 
for the treatment of human ailments/diseases. 
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3. Experimental 
3.1 Preparation of methyl-O-methyl podocarpate (22)  
25 g of crude podocarpic acid was weighed in a 300 mL beaker and 25 g of ice was 
added into it. Then 25 mL of methanol was added to the beaker. This mixture was 
stirred then added 12 g pellets of sodium hydroxide. The solution was continually 
stirred to dissolve completely the podocarpic acid and sodium hydroxide, then it was 
cooled to 15
0
C in an ice bath. 21.5 mL of dimethyl sulfate was added into this solution 
in a period of 1 hour
52
. At the end this period, this solution solidified. This mixture was 
stirred for an addition of 30 minutes then added 50 mL water then it was filtered. The 
solid was dissolved in 50 mL water then filtered and dried to obtain 22 g a white solid. 
This solid was recrystallized to obtain 20 g of methyl-O-methylpodocarpate with m.p. 
of 125C. Yield was 82%. IR (Perkin Elmer Spectrometer, CHCl
3
):3000, 2950, 2900, 
2860, 1720, 1600, 1540, 1490, 1460, 1400, 1360, 1300, 1240, 1200, 1190, 1150, 1060, 
1020950, 760, 740 cm
-1
. 
1
H-NMR (Mercury 300 MHz): 6.95 (d), 6.8 (s), 6.65 (d), 3.85 
(s), 3.65 (s), 2.8 (m), 2.25 (m), 1.95 (m), 1.6 (m), 1.5 (m), 1.4 (m), 1.22 (m), 1.2 (s), 
1.15 (m), 1.05 (m), 1.00 (s) ppm. 
13
C-NMR (Mercury 300 MHz): 178, 158, 150, 130, 
128, 114, 112, 56, 52, 51, 44, 39.5, 38, 31, 28, 25, 22.5, 20.5, 20 ppm. MS: 302(44), 
287(6), 228(16), 227(100), 173(6), 170(23), 147(10), 121(6), 91(4).  
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3.2 Preparation of 13-Iodomethyl-O-Methylpodocarpate (23)   
3.025 g of methyl-O-methylpodocarpate was weighed and transferred into a 500 mL 
volumetric flask, and then it dissolved in 60 mL of acetic acid. In a separated beaker, 2 
g of mercury (II) acetate was weighed and dissolved in 60 mL of acetic acid, and then 
this content was added into the flask above. This solution was heated to 70C and stirred 
for 15 minutes. A solution of iodine was prepared by dissolving of 7.614 g of iodine in 
240 mL of warm acetic acid. This iodine solution was then added drop wise in a period 
of 45 minutes into the flask while the temperature maintained at 70C during this period. 
At the end of this period, the solution was stirred for an addition 1 hour then cooled the 
flask to 15C in an ice bath, the solution was filtrated and the filtrate was added into 500 
mL of cold water in a 1L beaker. The resulting precipitate was filtered to yield 3 g of 
product. The product was recrystallized from acetone to obtain 2 g of pure product with 
m.p.149C, yield95%. IR (Perkin Elmer Spectrometer, CHCl
3
): 3000, 2940, 2850, 2400, 
1720, 1600, 1495, 1470, 1440, 1390, 1350, 1300, 1250, 1200, 1150, 1050, 950, 900, 
800, 750, 650 cm-1.1H-NMR (Mercury 300 MHz):7.45(s), 6.65 (s), 3.95 (s), 3.85 (s), 
2.70 (m), 2.20 (m), 1.95(m), 1.6 (m), 1.5 (m), 1.25 (s), 1.15 (m), 1.02 (s), 0.95 (m) ppm. 
13
C-NMR (Mercury 300 MHz): 178, 156, 150, 140, 131, 108, 83, 56.5, 52.5, 52, 44, 39, 
38.5, 32, 31.5, 29.5, 23, 21, 20 ppm. HRMS (Finnegan Spectrometer): 428(100), 
413(8), 381(3), 368(3), 353(77), 313(4), 287(6), 272(6), 227(15), 211(4), 172(6), 
140(5),129(8),115(6),101(3),91(2).  
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3.3 Preparation of 13-methoxy methyl-O-methyl podocarpate (24) 
2.14 g 13-iodo methyl-O-methyl podocarpate was weighed in a 100 mL round bottom 
flask and dissolved in 0.32 g of N, N-dimethyl formamide. 0.405 g of sodium 
methoxide was added to 0.34g of methanol in a separate beaker. The content inside the 
beaker was added to the flask and magnetic stirrer was added. Then the flask was 
heated by using heating mantle with continuous stirring till the temperature of solution 
reached 110C. At 110C, 0.1 g Copper (I) iodide was added. Then condenser was 
connected and reflux at 110C for four hours while monitoring the reaction with TLC.  
After the completion of the reaction, the solution was allowed to cool. The precipitate 
formed and filtered. The precipitate was washed with 100 mL ethyl acetate. The filtrate 
was evaporated to obtain 2 g of solid. Normal phase open column chromatography was 
performed to obtain 0.58 g 13-methoxy methyl-O-methyl podocarpate with m.p 143C. 
Yield was 84%. IR (Perkin Elmer Spectrometer, CHCl3): 3000, 2940, 2850, 2400, 
1720, 1600, 1495, 1470, 1440, 1390, 1350, 1300, 1250, 1200, 1150, 1050 cm-1. 1H 
NMR (Mercury 300 MHz): 7.52(s), 7.32(s), 6.73(s), 3.95(s), 3.85(s), 3.62(s), 2.80(m), 
2.28(m), 2.02(m), 1.64(m), 1.30(s), 1.22(s), 0.81(s) ppm. 13C NMR (Mercury 300 
MHz): 178, 158, 151, 148, 146.1, 132, 110.5, 57.2, 52, 50.2, 44.3, 38, 36, 30, 28, 22, 
20, 18 ppm. MS (Finnegan spectrometer): 333.4(30), 332(14), 302.4(82), 220.3(18), 
155.1(100). 
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3.4 Preparation of 13-ethoxy methyl-O-methyl podocarpate (25) 
2.14 g 13-iodo methyl-O-methyl podocarpate was weighed in a 100 mL round bottom 
flask and dissolved in 5 mL of N, N-dimethyl formamide. 0.51 g of sodium ethoxide 
was added to 0.54g of ethanol in a separate beaker. The content inside the beaker was 
added to the flask and magnetic stirrer was added. Then the flask was heated by using 
heating mantle with continuous stirring till the temperature of solution reached 110C. 
At 110C, 0.1 g Copper (I) iodide was added. Then condenser was connected and reflux 
at 110C for four hours while monitoring the reaction with TLC.  After the completion 
of the reaction, the solution was allowed to cool. The precipitate formed and filtered. 
The precipitate was washed with 100 mL ethyl acetate. The filtrate was evaporated to 
obtain 2 g of solid. Normal phase open column chromatography was performed to 
obtain 0.64 g 13-ethoxy methyl-O-methyl podocarpate with m.p 146C. Yield was 88%. 
IR (Perkin Elmer Spectrometer, CHCl3): 3000, 2940, 2850, 2400, 1720, 1600, 1495, 
1470, 1440, 1390, 1350, 1300, 1250, 1200, 1150, 1050 cm-1. 1H NMR (Mercury 300 
MHz): 7.45(s), 7.25(s), 4.04(m), 3.95(s), 3.85(s), 2.80(m), 2.28(m), 2.02(m), 1.64(m), 
1.30(s), 1.22(s), 0.81(s) ppm. 13C NMR (Mercury 300 MHz): 178, 150, 142, 140,132, 
108, 106, 65.2, 56, 52.2, 44.3, 40, 36, 30, 28, 22, 20, 18, 14 ppm. MS (Finnegan 
spectrometer): 347.4(25), 346 (10), 302.4(58), 220.3(18), 155.1(100). 
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3.5 Preparation of 13-propoxy methyl-O-methyl podocarpate (26) 
2.14 g 13-iodo methyl-O-methyl podocarpate was weighed in a 100 mL round bottom 
flask and dissolved in 5 mL of N, N-dimethyl formamide. 0.55 g of sodium propoxide 
was added to 0.54g of propanol in a separate beaker. The content inside the beaker was 
added to the flask and magnetic stirrer was added. Then the flask was heated by using 
heating mantle with continuous stirring till the temperature of solution reached 110C. 
At 110C, 0.1 g Copper (I) iodide was added. Then condenser was connected and reflux 
at 110C for four hours while monitoring the reaction with TLC.  After the completion 
of the reaction, the solution was allowed to cool. The precipitate formed and filtered. 
The precipitate was washed with 100 mL ethyl acetate. The filtrate was evaporated to 
obtain 2.2 g of solid. Normal phase open column chromatography was performed to 
obtain 0.67 g 13-propoxy methyl-O-methyl podocarpate with m.p 148C. Yield was 
84%. IR (Perkin Elmer Spectrometer, CHCl3): 3000, 2940, 2850, 2400, 1720, 1600, 
1495, 1470, 1440, 1390, 1350, 1300, 1250, 1200, 1150, 1050 cm-1. 1H NMR (Mercury 
300 MHz): 6.82(s), 6.73(s), 4.01(m), 3.95(s), 3.85(s), 3.12(m), 1.80(m), 1.60(m),  
1.40(s), 1.02(s), 0.81(s) ppm. 13C NMR (Mercury 300 MHz): 178, 146, 144, 142, 132, 
110.5, 108.2, 70.4, 58, 53.8, 52, 44.3, 38, 36, 32, 30, 28, 22, 20, 19, 18, 14 ppm. MS 
(Finnegan spectrometer): 361.2(16), 360(5), 302(68), 220.3(18), 155.1(100). 
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